Evaluation and Modeling with the Therapeutic Effects Group
Members
Maîtresse de conférences - praticienne hospitalière
UCBL
Tel: 04 72 11 94 07
Maître de conférences - praticien hospitalier
UCBL
Tel: 33 04 72 32 34 87
Professeur des universités - médecin généraliste
UCBL
Tel: 04 78 74 18 18
Maîtresse de conférences
UCBL
Tel: 33 04 78 78 57 83
Professeure des universités - médecin généraliste
UCBL
Tel: 04 78 77 72 86
Professeur d'université - praticien hospitalier
UCBL
Tel: 04 72 44 81 42
Doctorante
HCL
Assistant hospitalier universitaire
UCBL
Doctorant
UCBL
Tel: 04 72 44 81 42
Professeur d'université - praticien hospitalier
UCBL
Tel: 33 04 72 16 80 99
Doctorante
autre
Tel: 04 72 44 81 42
Praticien hospitalier
HCL
Tel: 04 72 44 81 42
Professeur d'université - praticien hospitalier émérite
UCBL
Professeur d'université - praticien hospitalier
UCBL
Tel: 04 27 85 77 32
Professeur d'université - praticien hospitalier
UCBL
Tel: 33 04 78 86 33 01
Maîtresse de conférences - praticienne hospitalière
UCBL
Maître de conférences - praticien hospitalier
UCBL
Tel: 04 72 11 94 20
Doctorant
HCL
Tel: 04 72 44 81 42
Doctorante
UCBL
Professeur d'université - praticien hospitalier
UCBL
Tel: 33 04 72 12 94 37
Post-doc
UCBL
Professeur d'université - praticien hospitalier émérite
UCBL
Doctorante
UCBL
Tel: 04 72 44 81 42
Stagiaire
HCL
EMET presentation
The EMET team brings together doctors, pharmacists and research professors specializing in the evaluation and use of drug and non-drug therapies, around a single project built on two axes:
- the evaluation of therapies in clinical trials or observational studies;
- the construction of explanatory and predictive models, to better understand and therefore predict the effect of therapies, simulate their impacts at the individual and population level, and improve the innovation paradigm.
The EMET team is therefore part of two major dynamics in therapy: analysis of the level of evidence and precision medicine.
The fields of application are cardiovascular and metabolic diseases, primary care medicine, rare pediatric diseases (including genetic and autoimmune diseases), oncology and infectious diseases.
EMET members implement approaches using different mathematical models: direct comparison and network meta-analysis, pharmacokinetic/pharmacodynamic analysis, Bayesian networks and machine learning.
Education
The EMET team is specially involved in the teaching of pharmacology and therapeutics and the modeling of the treatment effect through the coordination of the Masters 2 Clinical Evaluation (EC) and Pharmacology modeling and clinical trials (PHAME), Interpretation of Therapeutic Trials (IET), Training of investigators in clinical drug trials (FIEC) and Training of clinical research assistants and clinical study technicians (FARCTEC). Teacher-researchers are also involved in the first (pharmacology), second (pharmacology / therapeutics, pharmacy) and third cycles (general medicine, pediatrics, internal medicine) in health training courses.
Society involvement
The members of the EMET team through their work and their interactions with the other components of the LBBE, National societies, governmental (HAS) or international (EMA) agencies, and the Hospices Civils de Lyon, are invested in current societal issues: rationalization of the use of health product resources, research ethics, gender equality, rationality of approaches in analyzing the diversity of human populations.
Publications
Display of 1 to 30 publications on 517 in total
Taux de rémissions prolongées à l’arrêt d’un traitement par agoniste du récepteur de la thrombopoïétine au cours de la thrombopénie immunologique : suivi à long-terme de l’étude STOPAGO, cohorte prospective multicentrique
La Revue de Médecine Interne . 45 : A109
Journal article
see the publicationRisk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials
Joint Bone Spine . 91 ( 3 ) : 105673
Journal article
see the publicationDeaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate
Biomedicine and Pharmacotherapy . 171 : 116055
Journal article
see the publicationDifficult‐to‐treat primary immune thrombocytopenia in adults: Prevalence and burden. Results from the CARMEN ‐France registry
British Journal of Haematology . 204 ( 4 ) : 1476-1482
DOI: 10.1111/bjh.19288
Journal article
see the publicationDaptomycin pharmacokinetic/pharmacodynamic target in staphylococcal infections
Clinical Infectious Diseases .
DOI: 10.1093/cid/ciae018
Journal article
see the publicationPharmacokinetic Consideration of Venetoclax in Acute Myeloid Leukemia Patients: A Potential Candidate for TDM? A Short Communication
Therapeutic Drug Monitoring . 46 ( 1 ) : 127-131
Journal article
see the publicationRPEM : Randomized Monte Carlo parametric expectation maximization algorithm
CPT: Pharmacometrics and Systems Pharmacology . 13 ( 5 ) : 759-780
DOI: 10.1002/psp4.13113
Journal article
see the publicationWhat are the available online resources targeting psychosocial burden among stroke survivors and their informal caregivers: A scoping review
Digital Health . 10
Journal article
see the publicationExpositions accidentelles à des toxiques chez les enfants - Étude des données de plusieurs sources de recours aux soins entre 2014 et 2020
: 233 p.
Report
see the publicationUnlicensed/Off-Label Drug Prescriptions at Hospital Discharge in Children: An Observational Study Using Routinely Collected Health Data
Healthcare . 12 ( 2 ) : 208
Journal article
see the publicationExposure to ammonia solution due to substance use: a retrospective study from the French poison centres database (2009–2018)
Clinical Toxicology . : 1-5
Journal article
see the publicationNeurodevelopmental outcomes after prenatal exposure to lamotrigine monotherapy in women with epilepsy: a systematic review and meta-analysis
BMC Pregnancy and Childbirth . 24 ( 1 ) : 103
Journal article
see the publicationComparison of daptomycin and glycopeptide efficacy and safety for the treatment of Gram-positive infections: a systematic review and meta-analysis
Journal of Antimicrobial Chemotherapy .
DOI: 10.1093/jac/dkae026
Journal article
see the publicationAssociation between immune‐related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis
Fundamental & Clinical Pharmacology . 38 ( 2 ) : 369-379
DOI: 10.1111/fcp.12966
Journal article
see the publicationHeart and systemic sclerosis—findings from a national cohort study
Rheumatology .
Journal article
see the publicationHeart and systemic sclerosis—findings from a national cohort study
Rheumatology .
Journal article
see the publicationL’aspirine a-t-elle une place dans la prévention cardiovasculaire primaire par la polypill ? Étude de simulation sur une population virtuelle réaliste
Therapies . 78 ( 6 ) : 667-678
Journal article
see the publicationIncidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observatio
RMD Open . 9 ( 3 ) : e003064
Journal article
see the publicationCirculating microRNAs improve bacterial infection diagnosis and overall survival prediction in acute decompensation of liver cirrhosis
iScience . 26 ( 8 ) : 107427
Journal article
see the publicationPlatelet count threshold for hemorrhage in patients with immune thrombocytopenia treated with antiplatelet agents.
Blood .
Journal article
see the publicationPatients’ perceptions on clinical trials outcomes in pulmonary arterial hypertension therapy
Thorax . 78 ( 7 ) : 721-725
Journal article
see the publicationCirculating microRNAs improve bacterial infection diagnosis and overall survival prediction in acute decompensation of liver cirrhosis
iScience . 26 ( 8 ) : 107427
Journal article
see the publicationTreatment strategy for acquired pure red cell aplasia: a systematic review and meta-analysis
Blood Advances . 7 ( 21 ) : 6451-6465
Journal article
see the publicationPlatelet count threshold for hemorrhage in patients with immune thrombocytopenia treated with antiplatelet agents
Blood . 142 ( 12 ) : 1099-1101
Journal article
see the publicationProlonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study
Blood .
Journal article
see the publicationImmune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study
Blood . 141 ( 1 ) : 11-21
Journal article
see the publicationAUC-based monitoring and model-informed precision dosing of vancomycin in critically ill patients: why and how?
Anaesthesia Critical Care & Pain Medicine . 42 ( 6 ) : 101286
Journal article
see the publicationPopulation Pharmacokinetics of Vancomycin in Patients Receiving Hemodialysis in a Malian and a French Center and Simulation of the Optimal Loading Dose
Therapeutic Drug Monitoring . 45 ( 5 ) : 637-643
Journal article
see the publicationEvaluation of Limited Sampling Strategies for Bayesian Estimation of Daptomycin Area Under the Concentration–Time Curve: A Short Communication
Therapeutic Drug Monitoring . 45 ( 4 ) : 562-565
Journal article
see the publicationFrom Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure
Pharmaceutics . 15 ( 4 ) : 1081
Journal article
see the publication
You also, comment on this article